Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Micro Interventional Devices Receives FDA Approval of the STTAR-US IDE Pivotal Trial for its MIA™-T Percutaneous Tricuspid Annuloplasty System

Micro Interventional Devices (MID), a pioneering company in Transcatheter Tricuspid Valve Repair (TTVr) developing MIA-T (Minimally Invasive Annuloplasty – Tricuspid), a novel technology for the treatment of tricuspid annular disease, today announced that the U.S. Food & Drug Administration (FDA) has approved the company’s technology for Investigational Device Exemption (IDE) use, which allows the pivotal clinical trial to begin at notable U.S. hospitals. MID has been working closely with the FDA since receiving our Breakthrough Technology Designation.

The STTAR-US pivotal trial will provide an annular treatment utilizing MID’s proprietary, polymeric PolyCor™ anchors developed specifically for use in cardiac tissue. These anchors are deployed into the tricuspid annulus via 12F delivery catheters. The technology is designed to treat functional tricuspid valve disease by reducing annular area, minimizing Tricuspid Regurgitation (TR), and encouraging natural healing.

The STTAR-US Steering Committee is composed of thought leaders in the structural heart field. The trial will be led by two distinguished cardiologists as Principal Investigators, Bassem Chehab, MD who serves as an Associate Professor of Medicine at the University of Kansas and is the Director of Structural Cardiology, Clinical Cardiology and Research at Ascension Health, Wichita, Kansas and Saibal Kar, MD who serves as the Program Director Cardiovascular Disease Fellowship, Los Robles Regional Medical Center, Thousand Oaks, California and the National Physician Director, Interventional Cardiology HCA Healthcare US.

Significant unmet clinical needs exist in the treatment of TR with 1.6 million people in the US alone suffering from TR and only a small percentage of those patients are eligible to receive surgical treatment. MIA-T aims to address a large, untreated patient population and is unique among tricuspid repair and replacement technologies in its versatility and capability to treat patients who are ineligible for surgical or TEER procedures.

“This approval marks a critical milestone in the development of MIA-T. As one of the first percutaneous annular repair devices, we believe MIA-T will play a significant role in the emerging TTVr market. The global market is projected to exceed $3 billion annually by 2027, with rapid growth expected as minimally invasive options advance and adoption increases,” said Michael Whitman, Chief Executive Officer of Micro Interventional Devices. “With a rapidly growing global market and no established percutaneous standard of care for treating tricuspid regurgitation, we believe MIA-T has the potential to deliver both meaningful patient outcomes and significant value for our stakeholders.”

About Micro Interventional Devices, Inc. (MID):

MID is a privately held medical device company developing percutaneous solutions for structural heart disease. MID’s primary focus is repairing the tricuspid and mitral valves with catheters while the heart is beating, eliminating the need for sternotomy and cardiopulmonary bypass surgery.

MIA-T utilizes proprietary, compliant PolyCor™ anchors, the world’s first low mass polymeric implant designed to comply with normal physiological valvular function. The MIA-T implant is engineered to plicate and comply with cardiac tissue once deployed.

For more information please contact Christopher Whitman, Vice President of Finance.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.